UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1148-11
Program Prior Authorization/Notification
Medications Cerdelga® (eliglustat)
P&T Approval Date 12/2014, 11/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020, 10/2021,
10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Cerdelga® (eliglustat) is a glucosylceramide synthase inhibitor indicated for the long-term
treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers
(EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-
cleared test. CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of
Cerdelga to achieve a therapeutic effect. A specific dosage cannot be recommended for
CYP2D6 indeterminate metabolizers.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Cerdelga will be approved based on both of the following criteria:
a. Diagnosis of Gaucher disease type 1
-AND-
b. Patient is one of the following as detected by an FDA-cleared test:
(1) CYP2D6 extensive metabolizer
(2) CYP2D6 intermediate metabolizer
(3) CYP2D6 poor metabolizer
Authorization will be issued for 12 months.
B. Reauthorization
1. Cerdelga will be approved based on the following criterion:
a. Documentation of positive clinical response to Cerdelga therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program.
• Supply limits may be in place.
3. References:
1. Cerdelga [package insert]. Genzyme Ireland, Ltd. Waterford, Ireland. January 2024.
Program Prior Authorization/Notification - Cerdelga (eliglustat)
Change Control
12/2014 New program.
11/2015 Annual review. Updated to align with Indication Section of FDA label.
9/2016 Annual review. No changes to coverage criteria.
9/2017 Annual review. No changes.
9/2018 Annual review. No changes.
9/2019 Annual review. No changes to coverage criteria. Updated background
and references.
9/2020 Annual review. No changes to coverage criteria.
10/2021 Annual review. Updated reauthorization duration. Updated reference.
10/2022 Annual review. No changes to coverage criteria. Added state mandate.
Updated reference.
10/2023 Annual review. No changes to coverage criteria. Updated reference.
10/2024 Annual review. No changes to coverage criteria. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
2